Blackrock, INC Schedule 13G passive stakes
NYSE
SCHEDULE 13G/A: BlackRock Discloses 6.2% Passive Stake in Freeport-McMoRan Inc.
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 6.2% beneficial ownership stake in Freeport-McMoRan Inc. as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 9.8% Stake in Guidewire Software
BlackRock, Inc. has filed an amendment to its Schedule 13G, disclosing a 9.8% beneficial ownership stake in Guidewire Software, Inc. as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 6.3% beneficial ownership stake in Health Catalyst, Inc.'s common stock as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an Amendment No. 11 to its Schedule 13G, reporting a 6.7% beneficial ownership stake in Hess Corp's common stock as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an Amendment No. 7 to its Schedule 13G, disclosing a 7.3% beneficial ownership stake in Hilton Worldwide Holdings Inc. as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 8.1% Stake in IDEAYA Biosciences
BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 8.1% of IDEAYA Biosciences Inc.'s common stock as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an Amendment No. 15 to its Schedule 13G, disclosing a 9.4% beneficial ownership stake in IDEXX Laboratories Inc. as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 6.3% beneficial ownership stake in INOVIO PHARMACEUTICALS INC as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 8.2% Passive Stake in Intellia Therapeutics
BlackRock, Inc. has filed an updated Schedule 13G, revealing a passive beneficial ownership of 8.2% of Intellia Therapeutics, Inc.'s common stock as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Amends Stake in Intercontinental Exchange, Disclosing 6.8% Beneficial Ownership
BlackRock, Inc. has filed an Amendment No. 12 to Schedule 13G, disclosing its beneficial ownership of 6.8% of Intercontinental Exchange, Inc.'s common stock as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 5.9% Passive Stake in iShares Core MSCI International Developed Markets ETF
BlackRock, Inc. has filed an amended Schedule 13G, confirming its beneficial ownership of 5.9% of the common stock in the iShares Core MSCI International Developed Markets ETF as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, revealing a beneficial ownership of 8.3% of Kimball Electronics Inc.'s common stock as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 6.6% beneficial ownership stake in MarketAxess Holdings Inc. as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 6.7% passive beneficial ownership stake in Mersana Therapeutics Inc. as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an Amendment No. 12 to its Schedule 13G, reaffirming its passive beneficial ownership of 6.7% of Mosaic Co.'s common stock as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 5.4% of 1-800-FLOWERS.COM, Inc.'s Class A Stock as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 5.3% Passive Stake in ON24 Inc.
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 5.3% passive beneficial ownership stake in ON24 Inc.'s common stock as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an Amendment No. 5 to Schedule 13G, reporting a beneficial ownership of 7.7% in Orthofix Medical Inc. as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 6.1% Passive Stake in Piedmont Lithium Inc.
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 6.1% passive beneficial ownership stake in Piedmont Lithium Inc. as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 5.6% beneficial ownership stake in Puma Biotechnology Inc. as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 7.9% Stake in Q2 Holdings, Inc. Common Stock
BlackRock, Inc. has filed an Amendment No. 5 to Schedule 13G, reporting a beneficial ownership of 7.9% in Q2 Holdings, Inc.'s common stock as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 8.4% Passive Stake in Quest Diagnostics
BlackRock, Inc. has filed an amended Schedule 13G, revealing a passive beneficial ownership of 8.4% of Quest Diagnostics Inc.'s common stock as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Amends Stake in Rayonier Advanced Materials, Disclosing 7.1% Passive Ownership
BlackRock, Inc. has filed an amended Schedule 13G, revealing a 7.1% beneficial ownership stake in Rayonier Advanced Materials Inc. as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 5.6% beneficial ownership stake in Red Violet, Inc. as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 6.1% Stake in Relay Therapeutics
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 6.1% beneficial ownership stake in Relay Therapeutics, Inc. as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock, Inc. Discloses 15.3% Stake in SITE Centers Corp.
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 15.3% beneficial ownership stake in SITE Centers Corp. as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 6.1% beneficial ownership stake in South Plains Financial, Inc. as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 7.8% Stake in Syndax Pharmaceuticals
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 7.8% beneficial ownership stake in Syndax Pharmaceuticals Inc. as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an Amendment No. 15 to its Schedule 13G, disclosing a 7.7% beneficial ownership stake in VeriSign Inc.'s common stock as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 6.1% passive beneficial ownership stake in Vertex, Inc.'s Class A Stock as of March 31, 2025.